FrancophonIA/ELRC3.0 huggingface dataset:
English: It works by blocking the receptors to which histamine, a substance in the body that causes allergic symptoms,
Estonian: See blokeerib retseptorid, mille külge tavaliselt kinnitub organismis allergiasümptomeid põhjustav aine histamiin.
English: Desloratadine ratiopharm is a medicine containing the active substance desloratadine.
Estonian: Desloratadine ratiopharm on ravim, mis sisaldab toimeainena desloratadiini.
English: Because Desloratadine ratiopharm is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Aerius.
Estonian: Et Desloratadine ratiopharm on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Desloratadine ratiopharmi bioekvivalentsust võrdlusravimiga Aerius.
English: Desloratadine ratiopharm is a ‘generic medicine'.
Estonian: Desloratadine ratiopharm on geneeriline ravim.
English: The active substance in Desloratadine ratiopharm, desloratadine, is an antihistamine.
Estonian: Desloratadine ratiopharmi toimeaine desloratadiin on antihistamiin.
English: Why has Desloratadine ratiopharm been approved?
Estonian: Miks Desloratadine ratiopharm heaks kiideti?
English: What is Desloratadine ratiopharm?
Estonian: Mis on Desloratadine ratiopharm?
English: What is Desloratadine ratiopharm used for?
Estonian: Milleks Desloratadine ratiopharmi kasutatakse?
English: What are the benefits and risks of Desloratadine ratiopharm?
Estonian: Milles seisneb Desloratadine ratiopharmi kasulikkus ja mis riskid ravimiga kaasnevad?
English: How has Desloratadine ratiopharm been studied?
Estonian: Kuidas Desloratadine ratiopharmi uuriti?
English: How does Desloratadine ratiopharm work?
Estonian: Kuidas Desloratadine ratiopharm toimib?
English: How is Desloratadine ratiopharm used?
Estonian: Kuidas Desloratadine ratiopharmi kasutatakse?
English: This summary was last updated in 12-2017.
Estonian: Kokkuvõtte viimane uuendus: 12-2017.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cubicin on 19 January 2006.
Estonian: Euroopa Komisjon andis Cubicini müügiloa, mis kehtib kogu Euroopa Liidus, 19. jaanuaril 2006.
English: What measures are being taken to ensure the safe and effective use of Cubicin?
Estonian: Mis meetmed võetakse, et tagada Cubicini ohutu ja efektiivne kasutamine?
English: The full EPAR for Cubicin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Cubicini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Cubicin
Estonian: Muu teave Cubicini kohta
English: Cubicin is an antibiotic medicine, which is used to treat the following bacterial infections:
Estonian: Cubicin on antibiootikum, mida kasutatakse järgmiste bakteriaalsete infektsioonide raviks:
English: The European Medicines Agency decided that Cubicin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Euroopa Ravimiamet otsustas, et Cubicini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: ‘Complicated' means that the infection is difficult to treat, because it has spread to the deep tissues below the skin, treatment with surgery might be needed, or the patient has other conditions that might affect how well treatment works;
Estonian: „Tüsistunud” tähendab, et infektsiooni on raske ravida, sest see on kas levinud sügavale nahaalustesse kudedesse, võib vajada kirurgilist ravi või on patsiendil muud seisundid, mis võivad vähendada ravi efektiivsust.
English: Cubicin daptomycin
Estonian: Cubicin daptomütsiin
English: This is a summary of the European public assessment report (EPAR) for Cubicin.
Estonian: See on ravimi Cubicin Euroopa avaliku hindamisaruande kokkuvõte.
English: The duration of treatment with Cubicin depends on the risk of complications and official recommendations.
Estonian: Cubiciniga toimuva ravi kestus sõltub tüsistusriskist ja ametlikest soovitustest.
English: What is Cubicin and what is it used for?
Estonian: Mis on Cubicin ja milleks seda kasutatakse?
English: Effectiveness varied between the two studies because of differences in the types of patients and infections being treated.
Estonian: Kummagi uuringu efektiivsustulemuste erinevus oli tingitud ravitud patsiendirühmade ja infektsioonide erinevustest.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cubicin have also been included in the summary of product characteristics and the package leaflet.
Estonian: Cubicini ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Prescribers should consider official guidance on the use of antibiotics.
Estonian: Ravimi määramisel tuleb järgida ametlikke antibiootikumide kasutamise suuniseid.
English: Why is Cubicin approved?
Estonian: Miks Cubicin heaks kiideti?
English: There was insufficient evidence to support the use of Cubicin to treat bacteraemia in patients who did not have either right-sided infective endocarditis or complicated skin and softtissue infections.
Estonian: Ei olnud piisavalt andmeid, et toetada Cubicini kasutamist bakterieemia raviks patsientidel, kellel ei ole parempoolset nakkuslikku endokardiiti ega naha või pehmete kudede tüsistunud infektsioone.
English: The company that markets Cubicin will provide all doctors who are expected to use Cubicin with a dosage card to ensure the safe use of the medicine.
Estonian: Cubicini turustaja varustab kõik Cubicini eeldatavasti määravad arstid annustamiskaardiga, et tagada ravimi ohutu kasutamine.
English: In the first two studies involving 1,118 adults with complicated skin and soft tissue infections (mainly wound infections and major abscesses), Cubicin was effective in 67% of patients in one study and in 85% in the other.
Estonian: Kahes esimeses uuringus, milles osales 1118 naha ja pehmete kudede tüsistunud infektsioonidega (peamiselt haavainfektsioonid ja suured abstsessid) täiskasvanut, oli patsiente, kellel oli Cubicin efektiivne, ühes uuringus 67% ja teises 85%.
English: The third study involved 246 adults with bacteraemia caused by S. aureus, including 35 who also had right-sided infective endocarditis.
Estonian: Kolmandas uuringus osales 246 täiskasvanut, kellel oli S. aureus'e põhjustatud bakterieemia, sealhulgas oli 35 patsiendil ka parempoolne nakkuslik endokardiit.
English: It is not intended to provide practical advice on how to use Cubicin.
Estonian: Hindamisaruandes ei anta Cubicini kasutamise praktilisi nõuandeid.
English: Three main studies in adults and two in children aged between 1 and 17 years found that Cubicin was as effective as standard treatments at curing or improving infection.
Estonian: Kolmes täiskasvanute põhiuuringus ja ja kahes 1-17-aastaste laste põhiuuringus oli Cubicin infektsiooni ravis või leevendamisel sama efektiivne kui standardravi.
English: It can stop the growth of certain types of bacteria by attaching to the membrane surrounding the bacterial cell and upsetting the essential functions that keep the cell alive.
Estonian: See peatab teatud tüüpi bakterite kasvu, seondudes bakteriraku kestaga ja häirides raku elutegevuseks vajalikke põhifunktsioone.
English: What are the risks associated with Cubicin?
Estonian: Mis riskid Cubiciniga kaasnevad?
English: The first study in children and adolescents involved 396 patients with complicated skin and soft tissue infections without bacteraemia.
Estonian: Esimeses laste ja noorukite uuringus osales 396 naha või pehmete kudede tüsistunud infektsioonidega patsienti, kellel ei olnud bakterieemiat.
English: The second study in children and adolescents involved 73 patients with bacteraemia caused by S. aureus.
Estonian: Teises laste ja noorukite uuringus osales 73 S. aureus'e põhjustatud bakterieemiaga patsienti.
English: The most common side effects with Cubicin (seen in between 1 and 10 patients in 100) are infections caused by fungi (moulds and yeasts), urinary tract infections (infection of the structures that carry urine), Candida infection (a fungal infection), anaemia (low red blood cell counts), anxiety, insomnia (difficulty sleeping), dizziness, headache, hypertension (high blood pressure), hypotension (low blood pressure), gastrointestinal and abdominal pain (belly ache), nausea (feeling sick), vomiting, constipation, diarrhoea, flatulence (gas), bloating and distension (feeling as if the tummy is full), rash, pruritus (itching), pain in the limbs (arms or legs), infusion site reactions, pyrexia (fever), asthenia (weakness), abnormal liver tests and raised levels in the blood of an enzyme called CPK (a marker of muscle damage).
Estonian: Cubicini kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on seeninfektsioonid (hallitusvõi pärmseente põhjustatud infektsioonid), kuseteede infektsioonid, Candida infektsioon (teatud seeninfektsioon), aneemia (erütrotsüütide ehk vere punaliblede vähesus), ärevus, unetus, peapööritus, peavalu, kõrge vererõhk, madal vererõhk, kõhuvalu, iiveldus, oksendamine, kõhukinnisus, kõhulahtisus, kõhupuhitus, gaaside kogunemine ja kõhu paisumine, lööve, kihelus, jäsemevalu, infusioonikoha reaktsioonid, palavik, nõrkus, ebanormaalsed maksanäitajad ja lihasekahjustuste markeri ensüümi kreatiinfosfokinaasi (CPK) sisalduse suurenemine veres.
English: Cubicin is given into a vein as an infusion lasting 30 minutes or as an injection lasting 2 minutes.
Estonian: Cubicini manustatakse veeni kas 30 minutit kestva infusioonina või 2 minutit kestva süstena.
English: The decision to treat this type of infection with Cubicin should be based on the likelihood that the medicine will work against the infection and on advice from an expert;
Estonian: Otsus, kas ravida sellist infektsiooni Cubiciniga, peab põhinema ravimi tõenäolisel infektsioonivastasel toimel ja spetsialisti nõuandel.
English: It is used in adults when the bacteraemia is associated with either of the two infections above, or in adolescents and children from 1 year of age when the bacteraemia is associated with complicated infections of the skin and soft tissue.
Estonian: Cubicini kasutatakse täiskasvanutel, kelle bakterieemiat seostatakse ühega kahest eespool nimetatud infektsioonist, või noorukitel ja vähemalt 1-aastastel lastel, kelle bakterieemiat seostatakse naha ja pehmekoe tüsistunud infektsioonidega.
English: For the full list of side effects and restrictions with Cubicin, see the package leaflet.
Estonian: Cubicini kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The active substance in Cubicin, daptomycin, is an antibiotic that belongs to the group ‘lipopeptides'.
Estonian: Cubicini toimeaine daptomütsiin on lipopeptiidide rühma kuuluv antibiootikum.
English: Standard treatments comprised use of antibiotics such as vancomycin, a penicillin (including oxacillin, cloxacillin, flucloxacillin and nafcillin) or a cephalosporin.
Estonian: Standardravi tähendas antibiootikumide (nt vankomütsiini), penitsilliinravimite (sh oksatsilliini, kloksatsilliini, flukloksatsilliini ja naftsilliini) või tsefalosporiinravimi kasutamist.
English: • right-sided infective endocarditis (infection of the lining or the valves of the right side of the heart) caused by the bacterium Staphylococcus aureus (S. aureus) in adults.
Estonian: • Bakterist Staphylococcus aureus (S. aureus) põhjustatud parempoolne nakkuslik endokardiit (südame parempoolse osa südamesisekesta või südameklappide infektsioon) täiskasvanutel.
English: For practical information about using Cubicin, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Cubicini kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Cubicin contains the active substance daptomycin.
Estonian: Cubicin sisaldab toimeainena daptomütsiini.
English: For more information about treatment with Cubicin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Cubiciniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Cubicin is given by infusion lasting 60 minutes in children aged 1 to 6 years and 30 minutes in those aged above 7 years.
Estonian: 1-6-aastastel lastel manustatakse Cubicini 60 minutit kestva infusioonina ja üle 7-aastastel lastel 30 minutit kestva infusioonina.
English: Serious side effects include hypersensitivity (allergic) reactions, eosinophilic pneumonia (infection of the lungs), drug rash with eosinophilia and systemic symptoms (DRESS, a severe reaction affecting the skin, blood and internal organs), angioedema (rapid swelling of deeper skin tissues) and rhabdomyolysis (breakdown of muscle fibres).
Estonian: Rasked kõrvalnähud on ülitundlikkus (allergilised reaktsioonid), eosinofiilne kopsupõletik, ravimlööve koos eosinofiilia ja süsteemsete sümptomitega (DRESS, siseelundi-, naha- ja verehäireid tekitav raske reaktsioon), angioödeem (sügavamate nahakudede kiiresti tekkiv turse) ja rabdomüolüüs (lihasekiudude lagunemine).
English: • bacteraemia (infection of the blood) caused by S. aureus.
Estonian: • S. aureus'e põhjustatud bakterieemia (bakterveresus).
English: How is Cubicin used?
Estonian: Kuidas Cubicini kasutatakse?
English: • complicated infections of the skin and soft tissue below the skin in patients from 1 year of age.
Estonian: • Naha või nahaaluse pehme koe tüsistunud infektsioonid vähemalt 1-aastastel patsientidel.
English: What benefits of Cubicin have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Cubicini kasulikkus?
English: Treatment was successful in 88% (227 out of 257) of the patients receiving Cubicin compared with 86% (114 out of 132) receiving standard treatment.
Estonian: Eduka raviga patsiente oli Cubicini uuringurühmas 88% (227 patsienti 257st) ning standardravi rühmas 86% (114 patsienti 132st).
English: How does Cubicin work?
Estonian: Kuidas Cubicin toimib?
English: In the group with endocarditis, treatment was successful in 42% (8 out of 19) of the patients receiving Cubicin compared with 44% (7 out of 16) of the patients receiving standard treatment.
Estonian: Eduka raviga patsiente oli endokardiidiga patsientide uuringurühmas Cubicini kasutanutest 42% (8 patsienti 19st) ja standardravi kasutanutest 44% (7 patsienti 16st).
English: In children the dose of Cubicin for skin or soft tissue infection without bacteraemia depends on the child's age and ranges between 5 and 10 mg/kg once a day.
Estonian: Naha või pehmekoe infektsiooniga bakterieemiata lastel oleneb Cubicini annus lapse vanusest ja on vahemikus 5-10 mg/kg üks kord ööpäevas.
English: Cubicin is available as a powder that is made up into a solution for injection or infusion (drip) into a vein.
Estonian: Cubicini turustatakse süste- või infusioonilahuse (veeni tilgutatava lahuse) pulbrina.
English: For endocarditis and for skin or soft tissue infection with bacteraemia, the dose is 6 mg/kg once a day.
Estonian: Bakterieemiaga endokardiidi ja naha või pehmekoe infektsiooni korral on annus 6 mg/kg üks kord ööpäevas.
English: Treatment was successful in 88% (45 out of 51) of the patients receiving Cubicin compared with 77% (17 out of 22) receiving standard treatment.
Estonian: Eduka raviga patsiente oli Cubicini uuringurühmas 88% (45 patsienti 51st) ning standardravi rühmas 77% (17 patsienti 22st).
English: In adults, for skin or soft tissue infections without bacteraemia, Cubicin is given at a dose of 4 mg/kg body weight once a day.
Estonian: Naha või pehmekoe infektsioonidega bakterieemiata täiskasvanutele manustatakse Cubicini annuses 4 mg kehamassi kilogrammi kohta (mg/kg) üks kord ööpäevas.
English: Higher doses (between 7 and 12 mg/kg once a day) are used if the skin or soft tissue infection is associated with bacteraemia.
Estonian: Kui naha või pehmekoe infektsiooniga kaasub bakterieemia, kasutatakse suuremaid annuseid (7-12 mg/kg üks kord ööpäevas).
English: The medicine can only be obtained with a prescription.
Estonian: Cubicin on retseptiravim.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom sedation and analgesia depend on the dose that is used.
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom sügavus sõltuvad kasutatavast annusest.
English: The full EPAR for Cepedex can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Cepedexi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The Committee recommended that Cepedex be approved for use in the EU.
Estonian: Komitee soovitas Cepedexi kasutamise Euroopa Liidus heaks kiita.
English: Cepedex dexmedetomidine
Estonian: Cepedex deksmedetomidiin
English: It also depends on the use and the way it is given.
Estonian: Annus oleneb ka kasutamisest ja manustamisviisist.
English: • as premedication before inducing general anaesthesia.
Estonian: • eelravim enne üldanesteesia alustamist.
English: The company provided information on the quality and manufacture of Cepedex.
Estonian: Ettevõte esitas Cepedexi kvaliteedi ja tootmise andmed.
English: The European Commission granted a marketing authorisation valid throughout the EU for Cepedex on 13 December 2016.
Estonian: Euroopa Komisjon andis Cepedexile müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 13/12/2016.
English: Cepedex is used in non-invasive procedures which do not involve breaking the skin or a body cavity.
Estonian: Cepedexi kasutatakse mitteinvasiivsetel protseduuridel, millega ei kaasne naha läbistamist ega kehaõõnsustesse tungimist;
English: Cepedex is a medicine used to sedate (calm down) dogs and cats in the following situations:
Estonian: Cepedexi kasutatakse koerte ja kasside rahustamiseks järgmistel juhtudel:
English: This is a summary of the European public assessment report (EPAR) for Cepedex.
Estonian: See on ravimi Cepedex Euroopa avaliku hindamisaruande kokkuvõte.
English: Cepedex can also be used in dogs to provide pain relief and deep sedation when carrying out medical procedures and minor surgery where it is used in combination with butorphanol (a sedative and analgesic).
Estonian: Cepedexi tohib koertel kasutada ka valu leevendamiseks ja sügavaks sedatsiooniks meditsiinilistel protseduuridel ja väiksematel operatsioonidel koos butorfanooliga (sedatiivne aine ja analgeetikum).
English: It is not intended to provide practical advice on how to use Cepedex.
Estonian: Hindamisaruandes ei anta Cepedexi kasutamise praktilisi nõuandeid.
English: Dexmedetomidine is closely related to another substance used to sedate animals, medetomidine, that has been used in veterinary medicine for many years.
Estonian: Deksmedetomidiin on väga sarnane teise loomade sedatsiooniks kasutatava aine medetomidiiniga, mida on veterinaarias kasutatud aastaid.
English: What is Cepedex and what is it used for?
Estonian: Mis on Cepedex ja milleks seda kasutatakse?
English: For dogs the dose depends on their body surface area (calculated using bodyweight) and in cats it is based on bodyweight.
Estonian: Annus oleneb koertel kehapindalast (arvutatakse kehamassi järgi) ja kassidel kehamassist.
English: The duration and depth of
Estonian: Sedatsiooni ja analgeesia kestus ning
English: Other information about Cepedex?
Estonian: Muu teave Cepedexi kohta
English: Safety information has been included in the summary of product characteristics and the package leaflet for Cepedex, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers when giving Cepedex.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Cepedexi ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed Cepedexi andmisel.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that, in accordance with EU requirements, Cepedex has been shown to have comparable quality to Dexdomitor.
Estonian: Veterinaarravimite komitee järeldas, et Euroopa Liidu nõuete kohaselt on tõendatud ravimi Cepedex sarnane toime ravimiga Dexdomitor.
English: For practical information about using Cepedex, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Cepedexi kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: This means that Cepedex is similar to a ‘reference medicine' already authorised in the EU called Dexdomitor.
Estonian: See tähendab, et Cepedex on sarnane võrdlusravimiga Dexdomitor, millel juba on Euroopa Liidus müügiluba.
English: Why is Cepedex approved?
Estonian: Miks Cepedex heaks kiideti?
English: Because Cepedex is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Cepedex on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: No additional studies were needed as Cepedex is a generic medicine that is given by injection, is similar in composition to, and contains the same active substance as the reference medicine, Dexdomitor.
Estonian: Lisauuringuid ei olnud vaja, sest Cepedex on süstitav geneeriline ravim, mille koostis on sarnane võrdlusravimiga Dexdomitor ja mis sisaldab sama toimeainet.
English: Cepedex contains the active substance dexmedetomidine and is a ‘generic medicine'.
Estonian: Cepedex sisaldab toimeainena deksmedetomidiini ja see on geneeriline ravim.
English: It works by attaching to receptors known as alpha2-adrenergic receptors and preventing the release of the neurotransmitter noradrenaline from nerve cells in the body.
Estonian: Cepedex on alfa-2-adrenoretseptori agonist, mis seondub alfa-2-adrenergiliste retseptoritega ja takistab neurotransmitteri noradrenaliini vabanemist närvirakkudest.
English: In dogs, Cepedex is given by injection into a vein or a muscle.
Estonian: Koertele manustatakse Cepedexi veeni- või lihasesisese süstina.
English: Because Cepedex is a generic medicine and is bioequivalent to the reference medicine the precautions are the same as for the reference medicine.
Estonian: Et Cepedex on geneeriline ravim ja võrdlusravimiga bioekvivalentne, siis on meetmed samad, mis võrdlusravimi korral.
English: • when carrying out mildly to moderately painful procedures and examinations that require the animal to be restrained or sedated and made less sensitive to pain (analgesia).
Estonian: • rahustamist või analgeesiat (valu vaigistamist) vajavad kergelt või mõõdukalt valulikud ja liikumatut asendit nõudvad protseduurid ja uuringud koertel ja kassidel.
English: How does Cepedex work?
Estonian: Kuidas Cepedex toimib?
English: Therefore, the CVMP's view was that, as for Dexdomitor, the benefits outweigh the identified risks.
Estonian: Seetõttu on veterinaarravimite komitee arvamusel, et nagu ka Dexdomitori korral, ületab ravimi Cepedex kasulikkus kaasnevad riskid.
English: What are the benefits and risks of Cepedex?
Estonian: Milles seisneb Cepedexi kasulikkus ja mis riskid ravimiga kaasnevad?
English: How is Cepedex used?
Estonian: Kuidas Cepedexi kasutatakse?
English: How has Cepedex been studied?
Estonian: Kuidas Cepedexi uuriti?
English: Cepedex is available as a solution for injection and can only be obtained with a prescription.
Estonian: Cepedexi turustatakse süstelahusena ja see on retseptiravim.
English: In cats, it is given by injection into a muscle.
Estonian: Kassidele manustatakse Cepedexi lihasesisese süstina.
English: 1 pre-filled syringe of 150 mg + 2 needles, 1 prefilled syringe 100 mg + 2 needles
Estonian: 1 süstel 150 mg + 2 nõela, 1 süstel 100 mg + 2 nõela